Sigma® Life Science launches oncology disease model cell lines
21 February 2011 | By kdm communications limited
New cell lines offer cellular models of cancer that are expected to enhance development of drugs for personalised medicine...
List view / Grid view
21 February 2011 | By kdm communications limited
New cell lines offer cellular models of cancer that are expected to enhance development of drugs for personalised medicine...
17 February 2011 | By kdm communications limited
Sigma Life Science, today announced the release of OligoArchitect™...
13 December 2010 | By Sigma Life Science
Sigma Life Science, announced that its SAGE Labs initiative has successfully used its proprietary CompoZr® ZFN technology...
22 November 2010 | By kdm communications limited
Sigma Life Science, today announced the introduction of 1,700 new products to its collection of highly characterized Prestige Antibodies...
4 November 2010 | By kdm communications limited
JAX to distribute mouse models created using proprietary ZFN technology...
27 October 2010 | By kdm communications limited
Sigma Life Science, today announced a partnership between its SAGE Labs division...
14 September 2010 | By kdm communications limited
Sigma® Life Science, signed a 3 year contract with RCUK Shared Services Centre to be a prefered supplier for synthetic oligonucleotides...
9 August 2010 | By kdm communications limited
These ready-to-use reporter vectors are expected to simplify miRNA target validation...
5 August 2010 | By kdm communications limited
Sigma-Aldrich® announced it has entered into an agreement with the National Institutes of Health, and Boston University to develop...
12 December 2009 | By
The tremendous increase in the number of laboratories using qPCR and publications relying on qPCR data are testament to the rapid uptake of this technology. When preceded by reverse transcription (RT-qPCR) it is regarded as the reference technique for validation of previously derived data such as from microarray studies and…
9 October 2009 | By
A pivotal attraction of qPCR technology is its apparent lack of complication; an assay consisting of the simple procedure of combining oligonucleotides, PCR mastermix buffer and nucleic acid template to produce a qPCR reaction is perceived as undemanding. This practical simplicity is complemented by the absence of any requirement for…
30 July 2009 | By
The deceptive simplicity of a typical qPCR assay is an important reason for the exponential growth in the adoption of qPCR-related technologies for both research and diagnostic applications. The only requirements for obtaining ostensibly quantitative data are a mixing of primers, DNA and a mastermix, their distribution into individual tubes…
29 May 2009 | By
Real-time PCR (qPCR) data are reliable only if they result from a robust qPCR assay that has been carefully designed, validated and optimised. This process requires an extensive assay design procedure aimed at generating an optimum primer/probe/amplicon combination to allow accurate quantification of nucleic acids with minimum need for post-PCR…
20 March 2009 | By
The fluorescence-based quantitative real-time polymerase chain reaction (qPCR)1-3, is the most widely used method to detect and measure minute amounts of DNA in a wide range of samples extracted from numerous sources. Since all currently available thermostable polymerases are DNA-dependent, RNA must be converted ("reverse transcribed") into DNA prior to…
7 February 2009 | By Tania Nolan, Global Manager, Sigma-Aldrich and Stephen Bustin, Professor of Molecular Science, Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry
The fluorescence-based quantitative real-time polymerase chain reaction (qPCR)1-3, has the ability to detect and measure minute amounts of DNA in a wide range of samples extracted from numerous sources. In combination with reverse transcription (RT), the use of this technology has revolutionised life sciences, agriculture and medical research4,5. In addition,…